John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Opinion|Videos|February 4, 2026
Amy Luckenbaugh, MD, reflects on patient resilience, GU oncology advances for World Cancer Day
Author(s)Amy N. Luckenbaugh, MD
Fact checked by: Hannah Clarke
Amy N. Luckenbaugh, MD, FACS, shares what her patients have taught her about resilience as well as some of the advances in urologic oncology that are giving her hope.
Advertisement
In recognition of World Cancer Day on February 4, 2026, Amy N. Luckenbaugh, MD, FACS, shares what her patients have taught her about resilience as well as some of the advances in urologic oncology that are giving her hope. Luckenbaugh is a urologic oncology at Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
Closing Risk Stratification Gaps in Localized Prostate Cancer With AI
4
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
5